- Journal List
- Cureus
- v.16(6); 2024 Jun
- PMC11260203
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Cureus. 2024 Jun; 16(6): e62756.
Published online 2024 Jun 20. doi:10.7759/cureus.62756
PMCID: PMC11260203
PMID: 39036180
Monitoring Editor: Alexander Muacevic and John R Adler
Tushar Kalekar,1 Sai Pavan Kumar,1 and Apurvaa Pachva1
Author information Article notes Copyright and License information PMC Disclaimer
Abstract
Von Hippel-Lindau (VHL) syndrome is characterized by a range of tumors including phaeochromocytomas, pancreatic adenomas, cerebellar haemangioblastomas, and renal cell carcinomas. A 50-year-old male presented with a three-week history of headache. Additionally, the patient exhibited signs of hypertension. Ultrasonography (USG) abdomen and pelvis showed a solid mass lesion in the left adrenal gland, iso-echoic to the renal cortex. On contrast-enhanced computed tomography (CECT) of the brain, a well-defined solid cystic lesion was seen in the left posterior cerebellar hemisphere. Small nodular enhancing lesions were seen in the right cerebellar hemisphere. On further imaging with MRI brain contrast, the lesions in the cerebellum were diagnosed as multifocal hemangioblastomas. Laboratory investigations revealed elevated urinary metanephrines and normetanephrine, suggesting pheochromocytoma. Based on radiological and biochemical investigations, with the features of cerebellar haemangioblastomas and pheochromocytoma, a diagnosis of VHL syndrome was made.
Keywords: von hippel-lindau syndrome (vhl), ultrasonography (usg), ct (computed tomography) imaging, mri imaging, cerebellar hemangioblastoma, adrenal pheochromocytoma
Introduction
Von Hippel-Lindau (VHL) syndrome is inherited as an autosomal dominant gene. It occurs in 1 out of every 39,000 live births [1]. Mutations in the VHL gene may be passed down through generations and cause VHL [2,3]. The severity of this condition varies from person to person, but by the time a person reaches the age of 65, more than 90% of the affected individuals will have symptoms [4]. Certain abnormalities affecting the central nervous system (CNS) and the internal organs are seen in patients with VHL [5,6]. Neoplasms, such as hemangioblastomas and endolymphatic sac tumors, may form in the CNS. Respiratory cysts, pancreatic cysts, phaeochromocytomas, and cystadenomas of the adnexal organs (the broad ligament in women and the epididymis in men) are all possible visceral tumors. Patients with VHL had a median survival of 50 years until widespread monitoring and clearer guidelines for treating lesions associated with the disease became available [6,7]. Neurological hemangioblastoma and renal cell carcinoma (RCC) account for most deaths in VHL patients.
Case presentation
A 50-year-old man presented with a three-week history of intermittent episodes of holo cranial headache associated with nausea and dizziness and was admitted to the hospital as the symptoms aggravated for three days. The patient’s blood pressure was elevated to 220/110 mmHg, with all other vitals within normal ranges. The remainder of the physical examination was unremarkable. There was no significant family history. The patient had a normal diet and sleep, normal urine and defecation, no significant weight loss, and no other discomforts.
Ultrasonography (USG) of the abdomen and pelvis was performed using a Samsung HS-70A ultrasonograph (Samsung, Seoul, South Korea). Contrast-enhanced computed tomography (CECT) of the brain was done using a Philips Ingenuity 128-slice CT scanner (Philips Healthcare, Amsterdam, Netherlands). Magnetic resonance imaging (MRI) of the brain with Gadolinium contrast was done using the Siemens 3 Tesla Magnetom VIDA MRI (Siemens Healthineers, Erlangen, Germany).
USG of the abdomen and pelvis showed a solid mass lesion in the left adrenal gland (Figure (Figure1),1), which is isoechoic to the renal cortex.
Figure 1
Open in a separate window
Ultrasonography of the abdomen and pelvis
This figureshows a solid mass lesion in the left adrenal gland (blue arrow), which is iso-echoic to the left renal cortex (red arrow)
Non-contrast computed tomography of the brain was done, which revealed a well-defined solid cystic lesion in the left posterior cerebellar hemisphere (Figures (Figures2A2A--2B).2B). On post-contrast administration, the solid mural nodule shows avid post-contrast enhancement with a few tiny non-enhancing areas within - likely necrotic areas (Figures (Figures2C2C--2D).2D). The cystic component at the lateral aspect of the mural nodule showed peripherally enhanced walls in the contrast study.A small, enhancing lesion is seen in the right cerebellar hemisphere (Figure (Figure2D).2D). Surrounding hypodense vasogenic edema is seen,causing mild compression over the fourth ventricle, cerebral aqueduct, and quadrigeminal cistern.
Figure 2
Open in a separate window
Axial and coronal reformatted non-contrast and post-contrast computed tomography images of the brain
(A)-(B): Axial and coronal reformatted non-contrast computed tomography images show a solid cystic lesion in the left posterior cerebellar hemisphere (red arrows)
(C)-(D): Axial and coronal reformatted post-contrast images show avid post-contrast enhancement of solid mural nodules (red arrows), and a small enhancing lesion is seen in the right cerebellar hemisphere (black arrow)
Enhancing lesions are also noted in the cervical portion of the spinal cord (Figure (Figure3).3). The central canal of the spinal cord showed CSF density with no post-contrast enhancement, extending from the cervico-medullary junction to the C4 vertebra, suggestive of hydromelia, possibly with a syrinx (Figure (Figure3).3). Based on the above features, possible differentials of pilocytic astrocytoma with metastases or hemangioblastomas were given. Further evaluation with an MRI brain contrast was done.
Figure 3
Open in a separate window
Sagittal reformatted contrast-enhanced computed tomography image
This figure shows an enhancing lesion in the cervical spinal cord (blue arrow), with the central canal of the spinal cord above exhibiting hydromelia with a syrinx (yellow arrow), and an enhancing lesion in the left cerebellar hemisphere (red arrow)
MRI revealed a well-defined, solid cystic lesion appearing as T1 hypointense (Figure (Figure4A)4A) and T2 hyperintense (Figure (Figure4B),4B), and showing suppression on the fluid-attenuated inversion recovery (FLAIR) sequence (Figure (Figure4C).4C). Serpentine flow voids of vessels are seen overlying the lesion. The peripheral mural nodule appears isointense on T1 and hyperintense on T2, shows no diffusion restriction on diffusion-weighted imaging (DWI) (Figure (Figure4D),4D), and exhibits a high apparent diffusion coefficient (ADC) value (Figure (Figure4E).4E). A focus of blooming was noted on the gradient recalled echo sequence (GRE) in the mural nodule (Figure (Figure4F),4F), suggesting hemorrhage or calcification. Surrounding T2/FLAIR hyperintense vasogenic edema was noted (Figures (Figures2B2B--2C2C).
Figure 4
Open in a separate window
Multi-sequence MRI findings of a lesion in the left cerebellar hemisphere, demonstrating varied signal characteristics and associated features
A) Axial T1 MRI image showing a hypointense solid-cystic lesion in the left cerebellar hemisphere (red arrow); B)T2 axial MRI image showing a hyperintense cystic component (red arrow) with T2 hyperintense vasogenic edema (yellow arrow); C) FLAIR axial image showing a hypointense lesion in the left cerebellar hemisphere (red arrow) with surrounding FLAIR hyperintense vasogenic edema (yellow arrow); D) DWI image showing no areas of diffusion restriction in the lesion; E)ADC map showing a bright signal in the lesion (red arrow); F)GRE sequence showing a focus of blooming suggesting hemorrhage or calcification (red arrow)
FLAIR: Fluid attenuated inversion recovery; DWI: Diffusion-weighted imaging; ADC: Apparent diffusion coefficient; GRE: Gradient recalled echo
The mural nodule shows avid post-contrast enhancement with peripheral enhancing walls (Figure (Figure5A).5A). A small enhancing lesion is seen in the right cerebellar hemisphere (Figure (Figure5A).5A). Enhancing lesions are also noted in the cervical portion of the spinal cord (Figure (Figure5B).5B). The spinal cord in its central part shows fluid density with no post-contrast enhancement, extending from the cervico-medullary junction to the C4 vertebra, suggestive of syrinx (Figure (Figure5B5B).
Figure 5
Open in a separate window
Multi-sequence MRI findings illustrating lesions in the brain and spinal cord
A) MRI axial T1 post-contrast fat-saturated imageshows intense contrast enhancement of the mural nodule (red arrow) with peripheral enhancing walls. A small, enhancing lesion is seen in the right cerebellar hemisphere (yellow arrow)
B)Sagittal T1 post-contrast fat-saturated imageshows fluid density in the cervical spinal cord from the cervico-medullary junction to the C4 vertebra, suggesting hydromelia with a syrinx (white arrow). An enhancing lesion is noted in the cervical spinal cord (yellow arrow). Left cerebellar lesion showing post-contrast enhancement (red arrow)
MR spectroscopy within the mural nodule reveals a significant lipid/lactate peak, elevation of choline, and reduction in N-acetyl aspartate (NAA) (Figure (Figure6).6). MRI features mostly represented multifocal intracranial and spinal hemangioblastomas. Laboratory investigations revealed elevated urinary metanephrines and normetanephrine.
Figure 6
Open in a separate window
MR spectroscopy within the mural nodule
This figure reveals a significant lipid/lactate peak (white arrow), the elevation of choline (cho), and a reduction in N-acetyl aspartate (NAA), suggesting hemangioblastoma
Excision of the cerebellar tumor was done (Figure (Figure7A).7A). The hematoxylin and eosin (H&E) stained slide from tumor resection showed capillary channels with stromal cells and foamy cells with clear cytoplasm, diagnostic of hemangioblastoma (Figure (Figure7B7B).
Figure 7
Open in a separate window
Excision of the cerebellar tumor and H&E-stained slide from the tumor resection
A)Specimen of excised cerebellar tumor
B) The hematoxylin and eosin (H&E) stained slide from tumor resection showed capillary channels with stromal cells and foamy cells with clear cytoplasm, diagnostic of hemangioblastoma (H&E, x400)
Post-operative non-contrast computed tomography was performed. Craniotomy defect seen in the occipital region with multiple air foci and hemorrhagic foci seen underneath the site of the defect, mostly postoperative changes. Hypodensity and edema are seen in the right cerebellar hemisphere (Figure (Figure8).8). After two months of follow-up, the patient's neurological symptoms were relieved and relatively stable.
Figure 8
Open in a separate window
Post-operative non-contrast computed tomography
This figureshows a craniotomy defect (blue arrow) in the occipital region with multiple air foci and hemorrhagic foci (yellow arrow) underneath the site of the defect, mostly postoperative changes. Hypodensity and edema are also seen in the right cerebellar hemisphere (red arrow)
Discussion
Clinical criteria or genetic testing may confirm a diagnosis of VHL. For a patient to be diagnosed with VHL, they must have a history of the disease in their family as well as a CNS hemangioblastoma (including retinal hemangioblastomas),RCC, pheochromocytoma, or endothelial lining tumor. Two or more CNS hemangioblastomas, or one CNS hemangioblastoma plus a visceral tumor associated with VHL, will meet the clinical diagnostic criteria for VHL in about 20% of individuals without a family history of the disease [7,8].
In VHL, pheochromocytomas may be bilateral or numerous. The carotid body, glomus jugulare, and peri-aortic tissues may also host these tumors as extra-adrenal paragangliomas. According to research, 5% of pheochromocytomas are cancerous [9]. Although symptoms, such as headaches, pallor, nausea, tachycardia, palpitations, episodic sweating, and intermittent or chronic hypertension, are common in pheochromocytomas, 30% of patients may have no symptoms at all [9]. Imaging and laboratory tests confirm a pheochromocytoma diagnosis. In order to avoid a perioperative hypertensive crisis, it is essential to assess VHL patients before surgery. Through early surgical intervention and adrenal cortical-sparing surgery, patients are able to achieve long-term independence from corticosteroids with little recurrence.
A CNS hemangioblastoma of the cerebellum, brainstem, or spinal cord will develop in 60-80% of VHL patients throughout the course of their lifespan [5]. Several hemangioblastomas will occur in almost all of these individuals (around 90%). Hemangioblastomas are benign on histology, but they may cause serious illness and even death in VHL. The brainstem, cerebellum, or spinal cord account for virtually all cases of CNS hemangioblastomas (tumors outside the retina) (95% of tumors) [5,10,11]. Depending on the specific location of the tumor, patients with CNS hemangioblastomas may have a variety of symptoms. Headaches (75%), ataxia of gait (55%), dysmetria (29%), hydrocephalus (28%), and nausea/vomiting (28% of patients) are symptoms of cerebellar hemangioblastomas [12]. For the detection and monitoring of changes in hemangioblastomas, the most sensitive and reliable imaging technique is contrast-enhanced craniospinal MR imaging.
In a study that followed 19 patients with VHL for at least 10 years, Ammerman et al. [13] examined the trend of the development of CNS hemangioblastomas by serial imaging. In virtually all cases (97% of 143 tumors), hemangioblastomas exhibited a saltatory development pattern with bursts of fast growth interspersed with periods of relative quiet. The average number of quiescent periods between growth stages for hemangioblastomas was 1.85 before they became symptomatic and needed to be removed. On average, there were 13±15 months of growth phases and 25±19 months of growth quiescence periods. Radiographic progression was seen in almost all the hemangioblastomas (97%); however, only 50% of those tumors needed therapy to cause symptoms.
Most craniospinal hemangioblastomas may be safely removed, and hemangioblastoma complete resection is curative [12,14,15]. Patients will usually regain their pre-treatment neurologic condition within six weeks after CNS hemangioblastoma excision, and modest, transitory impairments in neurologic function are rare [5,12]. Surgery is often postponed until the onset of related symptoms occurs due to the multiplicity and unpredictable development rate of CNS hemangioblastomas [11,14]. This approach allows for the avoidance of needless surgical resection and the preservation of good neurologic function in the majority of VHL patients [14].
Conclusions
Multifocal intracranial and spinal hemangioblastomas pose diagnostic challenges due to their rare occurrence and diverse clinical presentations. Through meticulous imaging evaluation, including USG, CT, and MRI, coupled with advanced techniques like MR spectroscopy, we were able to accurately diagnose and delineate the extent of the lesions. Surgical excision remains the cornerstone of management, and histopathological examination remains crucial for a definitive diagnosis. This case highlights the importance of integrating clinical, radiological, and pathological findings to guide therapeutic strategies effectively.
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.
Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Author Contributions
Concept and design: Sai Pavan Kumar, Tushar Kalekar, Apurvaa Pachva
Acquisition, analysis, or interpretation of data: Sai Pavan Kumar, Tushar Kalekar, Apurvaa Pachva
Drafting of the manuscript: Sai Pavan Kumar, Tushar Kalekar, Apurvaa Pachva
Critical review of the manuscript for important intellectual content: Sai Pavan Kumar, Tushar Kalekar, Apurvaa Pachva
References
1. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Neumann HP, Wiestler OD. Lancet. 1991;4:1052–1054. [PubMed] [Google Scholar]
2. Identification of the von Hippel-Lindau disease tumor suppressor gene. Farida L, Kalman T, James G, et al. Science. 1993;260:1317–1320. [PubMed] [Google Scholar]
3. Somatic mutations in VHL germline deletion kindred correlate with mild phenotype. Wait SD, Vortmeyer AO, Lonser RR, et al. Ann Neurol. 2004;55:236–240. [PubMed] [Google Scholar]
4. Von Hippel-Lindau disease: a genetic study. Maher ER, Iselius L, Yates JR, et al. J Med Genet. 1991;28:443–447. [PMC free article] [PubMed] [Google Scholar]
5. Von Hippel-Lindau disease. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. Lancet. 2003;14:2059–2067. [PubMed] [Google Scholar]
6. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. Richard S, Campello C, Taillandier L, Parker F, Resche F. J Intern Med. 1998;243:547–553. [PubMed] [Google Scholar]
7. von Hippel-Lindau disease affecting 43 members of a single kindred. Lamiell JM, Salazar FG, Hsia YE. https://pubmed.ncbi.nlm.nih.gov/2642584/ Medicine. 1989;68:1–29. [PubMed] [Google Scholar]
8. von Hippel-Lindau disease: a clinical and scientific review. Maher ER, Neumann HP, Richard S. Eur J Hum Genet. 2011;19:617–623. [PMC free article] [PubMed] [Google Scholar]
9. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. Walther MM, Reiter R, Keiser HR, et al. J Urol. 1999;162:659–664. [PubMed] [Google Scholar]
10. Hemangioblastoma of the spinal cord. Review and report of five cases. Browne TR, Adams RD, Roberson GH. Arch Neurol. 1976;33:435–441. [PubMed] [Google Scholar]
11. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. J Neurosurg. 2003;98:82–94. [PubMed] [Google Scholar]
12. Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. Jagannathan J, Lonser RR, Smith R, DeVroom HL, Oldfield EH. J Neurosurg. 2008;108:210–222. [PubMed] [Google Scholar]
13. Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. Ammerman JM, Lonser RR, Dambrosia J, Butman JA, Oldfield EH. J Neurosurg. 2006;105:248–255. [PubMed] [Google Scholar]
14. Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. Lonser RR, Weil RJ, Wanebo JE, DeVroom HL, Oldfield EH. J Neurosurg. 2003;98:106–116. [PubMed] [Google Scholar]
15. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. Weil RJ, Lonser RR, DeVroom HL, Wanebo JE, Oldfield EH. J Neurosurg. 2003;98:95–105. [PubMed] [Google Scholar]
Articles from Cureus are provided here courtesy of Cureus Inc.